Overview

Liquid Biopsy Market Overview

Liquid biopsy market is anticipated to value over US$ 8.4 billion by the end of 2027 and expanding at a CAGR of over 20% during the forecast period, 2020 to 2027.

Liquid biopsy tests are executed to understand the molecular aspects of cancer across the healthcare and research settings, such as hospitals, physicians, pathological and research laboratories. It is a non-invasive blood test that could provide researchers, physicians, and surgeons with information about the cancer profile of the patient and appropriate therapy to improve the survival rate of cancer patients. It is a rapid process that usually includes a simple blood draw, extraction of nucleic acids from the blood plasma, and amplification of the molecular targets to permit analysis of the defined biomarkers. Easy and non-invasive access to the tumour genome, early cancer diagnosis & detection, characterization of new lesions, drug & therapeutic target identifications for cancer treatment are some advantages of liquid biopsies, which improve the safety and efficiency of cancer therapy for patients.

Increasing importance of non-invasive surgical techniques led to the rapid adoption of liquid biopsy in primary healthcare settings. Liquid biopsy is used for detection of epidermal growth factor receptor mutations and it appears in 10 to 35% of non-small cell lung cancer. Increasing prevalence of non-small cell lung cancer led to the robust growth of the market. According to the American Cancer Society, about 80-85% of lung cancer is non-small cell lung cancer and they are 228,150 newly diagnosed cases of lung cancer in 2019. Further, the rapid advancement of technologies augmented the existing technologies and led to the development of simple equipment. Along with this, increasing R&D investments in strengthening existing portfolios fuelled the growth of the market.

Developing economies like North America and Europe regions accounts more than 60% share of the global market. North America accounts major share in the global market due to high adoption. It is followed by Europe and it is majorly dominated by the UK, Germany, and France. Developing economies like the Asia Pacific and Latin America is the most opportunistic market space for manufacturers due to a limited number of manufacturers in these regions. These regions are expected to witness the highest growth rate during the forecast period. Rest of world accounts small fraction in the global market and it has the limited presence of manufacturers

Liquid Biopsy market players include:

Biocept, Inc., Qiagen Corporation, Roche Diagnostics, RainDance Technologies, Trovagene, Genomic Health, CellMax Life and others

Liquid Biopsy Market Trends, Share, Size and Forecast

Liquid Biopsy Market Segmentation

By Biomarker Type

ctDNA
Exosomes
CTC cells

By End User

Hospitals
Cancer Research Centres
Diagnostic Laboratories

By Region

North America
Latin America
Europe
Asia Pacific
Rest of the World

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global Liquid Biopsy Market by Biomarker Type, by End-User, and by Region

• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core competencies